Fibrocell Science Inc. (NASDAQ:FCSC) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 669,025 shares, a decline of 30.3% from the October 31st total of 959,239 shares. Based on an average trading volume of 123,299 shares, the days-to-cover ratio is presently 5.4 days. Approximately 2.5% of the shares of the stock are short sold.

Shares of Fibrocell Science (NASDAQ:FCSC) opened at 0.90 on Wednesday. The firm’s market cap is $39.58 million. Fibrocell Science has a 12-month low of $0.52 and a 12-month high of $6.18. The firm’s 50-day moving average price is $0.71 and its 200 day moving average price is $1.05.

Fibrocell Science (NASDAQ:FCSC) last announced its earnings results on Thursday, November 3rd. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. Fibrocell Science had a negative return on equity of 215.38% and a negative net margin of 7,362.25%. On average, equities analysts expect that Fibrocell Science will post ($0.35) earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in FCSC. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Fibrocell Science by 31.4% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 250,803 shares of the company’s stock valued at $288,000 after buying an additional 59,926 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Fibrocell Science by 54.6% in the second quarter. Janney Montgomery Scott LLC now owns 172,932 shares of the company’s stock valued at $199,000 after buying an additional 61,050 shares during the last quarter. Oxford Asset Management boosted its stake in shares of Fibrocell Science by 60.2% in the second quarter. Oxford Asset Management now owns 313,959 shares of the company’s stock valued at $361,000 after buying an additional 118,007 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of Fibrocell Science during the second quarter valued at approximately $111,000. Institutional investors own 56.63% of the company’s stock.

Several equities research analysts have commented on the stock. Zacks Investment Research cut shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research report on Tuesday, November 15th. Canaccord Genuity reiterated a “buy” rating and issued a $1.50 price target on shares of Fibrocell Science in a research report on Sunday, August 7th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Fibrocell Science has an average rating of “Buy” and a consensus target price of $4.65.

ILLEGAL ACTIVITY WARNING: “Short Interest in Fibrocell Science Inc. (FCSC) Declines By 30.3%” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/30/short-interest-in-fibrocell-science-inc-fcsc-declines-by-30-3.html.

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

5 Day Chart for NASDAQ:FCSC

Receive News & Stock Ratings for Fibrocell Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc. and related stocks with our FREE daily email newsletter.